The Latest Breaking News from Pfizer Inc

Pfizer Inc plans to sell its entire portfolio of brand-name drugs at cost in as many as 45 lower-income countries, including Cambodia and Laos, one of the most comprehensive and ambitious drug-access programmes ever announced by a large pharmaceutical manufacturer.

Pfizer Inc will make all of its patented medicines including COVID-19 treatment Paxlovid and big-selling breast cancer drug Ibrance available at a not-for-profit price to 45 of the world's poorest countries, the drugmaker said on Wednesday.

Pfizer Inc (NYSE:PFE) has announced detailed results from two pivotal studies from ELEVATE UC Phase 3 program evaluating etrasimod for active ulcerative colitis (UC).  The drug, etrasimod, was Pfizer's key asset in its $6.7 billion deal for Arena Pharmaceuticals last year.  UC is an inflammatory bowel disease that affects around 3.8 million people in North…

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial.  Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

Pfizer Inc. and BioNTech SE said their COVID-19 vaccine was highly effective and prompted a strong immune response in children under age 5, based on early results from a trial that is likely to pave the way for infants and toddlers to finally get immunized.

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

The Centers for Disease Control and Prevention recommended that children ages 5 to 11 receive the newly authorized COVID-19 booster shot from Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX). Following the recommendation, many of the nation's doctors, pharmacies, and other vaccination sites are expected to begin offering the extra doses to the 28 million U.S. children…

The U.S. National Institutes of Health and Pfizer Inc (NYSE:PFE) are discussing testing a longer course of COVID-19 antiviral treatment Paxlovid, required to prevent reinfections, White House Chief Medical Officer Anthony Fauci said. "We're going to be planning what studies we're going to be doing relatively soon, within the next few days," to…

Amid rising concerns over the potential development of resistance to Pfizer Inc's (NYSE:PFE) COVID-19 pill Paxlovid, the company has declined to supply researchers with the antiviral for use in combination studies, according to a Bloomberg report.  Researchers say that Paxlovid combined with other drugs might stave off resistance.  Pfizer hasn't started any combination…

The FDA has decided not to authorize fluvoxamine, an antidepressant, to treat COVID-19. The agency that data has not shown the drug to be an effective therapeutic for fighting the virus. "Based on the review of available scientific evidence, the FDA has determined that the data are insufficient to conclude that fluvoxamine…

The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine for children aged 5 to 11 probably by today, the New York Times reported, citing people familiar with the matter. The companies submitted an application to the FDA for authorization last month. They have cited data from…